SL-164
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H12Cl2N2O |
| Molar mass | 319.19 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SL-164, also known as dicloqualone or DCQ, is an analogue of methaqualone developed in the late 1960s by a team at Sumitomo.[1] SL-164 has similar sedative, hypnotic[2] and properties to the parent compound, but was never marketed for clinical use, due to higher risk of convulsions. Like other 4-substituted analogues, like methylmethaqualone, SL-164 may cause seizures.[3]
References
[edit]- ^ US 3651230, "Compositions And Methods For Tranquilizing With Substituted 3-Phenyl-4-Quinazolinone Derivatives"
- ^ Saito C, Sakai S, Yukawa Y, Yamamoto H, Takagi H (December 1969). "Pharmacological studies on 2-methyl-3(2'-methyl-4'-chlorophenyl)-5-chloro-4[H)-quinazolinone (SL-164)". Arzneimittel-Forschung. 19 (12): 1945–9. PMID 4985336.
- ^ Boltze KH, Dell HD, Lehwald H, Lorenz D, Rueberg-Schweer M (August 1963). "[Substituted 4-Quinazolinone Derivatives As Hypnotics]". Arzneimittel-Forschung (in German). 13: 688–701. PMID 14085923.
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |